Media headlines about AnaptysBio (NASDAQ:ANAB) have trended somewhat positive on Tuesday, according to Accern Sentiment. Accern rates the sentiment of news coverage by monitoring more than twenty million blog and news sources in real time. Accern ranks coverage of companies on a scale of negative one to positive one, with scores closest to one being the most favorable. AnaptysBio earned a news impact score of 0.06 on Accern’s scale. Accern also assigned media headlines about the biotechnology company an impact score of 45.7839036988075 out of 100, indicating that recent news coverage is somewhat unlikely to have an effect on the stock’s share price in the near term.
These are some of the news stories that may have effected Accern Sentiment Analysis’s scoring:
- AnaptysBio (ANAB) Cut to “Hold” at Zacks Investment Research (americanbankingnews.com)
- The Zacks Analyst Blog Highlights: AnaptysBio, , Roku, SMART Global Holdings, UroGen Pharma and Calyxt (finance.yahoo.com)
- Strange: Bullish ANAB Analysts Actually See -17.88% Downside (nasdaq.com)
- AnaptysBio Inc (ANAB) Receives Average Recommendation of “Buy” from Brokerages (americanbankingnews.com)
- 5 Best Performing IPOs of 2017 (finance.yahoo.com)
Shares of AnaptysBio (NASDAQ:ANAB) traded down $0.14 during mid-day trading on Tuesday, reaching $100.58. 359,326 shares of the company’s stock traded hands, compared to its average volume of 300,700. The company has a debt-to-equity ratio of 0.09, a quick ratio of 10.77 and a current ratio of 10.77. AnaptysBio has a twelve month low of $15.17 and a twelve month high of $103.16.
AnaptysBio (NASDAQ:ANAB) last announced its quarterly earnings data on Tuesday, November 7th. The biotechnology company reported ($0.45) EPS for the quarter, topping the consensus estimate of ($0.47) by $0.02. research analysts predict that AnaptysBio will post -1.72 earnings per share for the current year.
A number of research analysts recently weighed in on the stock. Zacks Investment Research raised shares of AnaptysBio from a “sell” rating to a “hold” rating and set a $74.00 price target on the stock in a research report on Friday, November 10th. SunTrust Banks assumed coverage on shares of AnaptysBio in a research report on Wednesday, November 15th. They set a “buy” rating and a $115.00 price target on the stock. Royal Bank of Canada raised their price target on shares of AnaptysBio from $40.00 to $79.00 and gave the company an “outperform” rating in a research report on Tuesday, October 10th. Credit Suisse Group raised their price target on shares of AnaptysBio from $38.00 to $85.00 and gave the company an “outperform” rating in a research report on Tuesday, October 10th. Finally, Wedbush reissued a “positive” rating and set a $82.00 price target (up from $75.00) on shares of AnaptysBio in a research report on Tuesday, November 7th. One investment analyst has rated the stock with a hold rating and eight have given a buy rating to the company’s stock. The company presently has an average rating of “Buy” and a consensus price target of $88.00.
AnaptysBio Company Profile
AnaptysBio, Inc is a United States-based biotechnology company. The Company is engaged in developing antibody product candidates focused on unmet medical needs in inflammation and immuno-oncology. The Company develops its product candidates using its antibody discovery technology platform, which is designed to replicate, in vitro, the natural process of antibody generation.
Receive News & Ratings for AnaptysBio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AnaptysBio and related companies with MarketBeat.com's FREE daily email newsletter.